StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a report issued on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Up 2.8 %
Shares of NASDAQ:TTNP opened at $3.69 on Monday. The firm’s 50-day moving average is $3.59 and its 200 day moving average is $4.13. Titan Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- What is a Bond Market Holiday? How to Invest and Trade
- How to Build the Ultimate Everything ETF Portfolio
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What Are Dividend Champions? How to Invest in the Champions
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
